Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer.
about
Pathways for aberrant angiogenesis in pancreatic cancerMet receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancerSimultaneous profiling of 194 distinct receptor transcripts in human cellsImmunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.Hepatocyte growth factor/scatter factor-induced intracellular signalling.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancerBiological approaches to therapy of pancreatic cancer.Chemoprevention strategies for pancreatic cancerCrizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancerMolecular biology of pancreatic cancer.Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components.Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitorsComparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinomaActivation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesisEnhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancerA novel transcriptional regulatory region within the core promoter of the hepatocyte growth factor gene is responsible for its inducibility by cytokines via the C/EBP family of transcription factorsNK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cellsGastrointestinal growth factors and hormones have divergent effects on Akt activation.Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.Role of MetMAb (OA-5D5) in c-MET active lung malignancies.Primary human fibroblasts induce diverse tumor invasiveness: involvement of HGF as an important paracrine factor.Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy.A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts.Overexpression of midkine in pancreatic duct adenocarcinomas induced by N-Nitrosobis(2-oxopropyl)amine in hamsters and their cell lines.Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer
P2860
Q24800215-40F1B893-7D70-4BB0-B4ED-061BAABC4AFBQ27334957-B58D92BD-9890-4210-A51C-5081D2FCBF8AQ30411399-6C83512F-6BAF-4ED4-9993-83F1C81E83BDQ30481528-3E3A0C24-8977-407A-AE88-41CF1D8DA3D1Q33863966-19983611-CE53-4E9E-A551-7314103DA1FBQ33886974-1B0F07F9-9333-4382-9F0E-31983E3D84DDQ33899938-397910C6-A71C-4DD9-B7A8-D335E8F090DCQ34082960-D36B89A1-C6B1-4BA9-86B0-635E4AC2A81FQ34619273-F86A6F7A-1C13-4156-9E17-92C25160B198Q35085975-EDF11928-D98C-44E1-92AA-9A3545B21BFCQ35399426-388297B2-7248-49EE-A857-00C34DAD6D30Q35691904-68B99BB3-A04A-4850-B534-9D4EAC2238B1Q35753107-868DE34F-8109-40FF-B2AC-B71610978B1DQ35753150-B82C6FC7-7535-475C-96CB-B8D6377D4CEAQ35796063-644662ED-B92B-4B34-ACC6-535152A82F8BQ35798481-3774ADC1-22A7-451C-B3B0-3DB93C6757AFQ36116282-12A1756C-FAF0-4077-85EB-1A04CFF901C0Q36236835-B19ED20A-743D-4334-B77B-82729EE42E9CQ36547939-AA7678CE-493F-41A0-B4A2-3F68C4625E01Q36572989-02CCD409-515C-42B7-8323-E71ED6F28E22Q36622822-7AC710CD-1D62-4879-AF7D-2D8FF55FA692Q37180159-5EE74639-E2D3-4285-B46D-880DA28CFB11Q37356529-932C86E9-8BDA-4255-B898-2EED35477B2EQ37448101-CA394C5E-FC56-40A3-8C66-930D8F077D03Q37952015-7FEB8144-27FB-42A9-A1C0-6B545EC6A3B2Q41152341-3BA1E51B-6FFF-4EEB-AF74-ADFA7454C455Q41205527-B19BA490-01FD-4CB1-AA30-541B20A49CB1Q41977380-FB95FCBE-BCBF-4828-BB73-2126199B97C3Q42017784-C82275D3-3C9C-41E1-841E-1EECC2C729C3Q54976417-734D47A4-AD8A-483F-A9CF-54DDADD780BEQ55052293-17126C8E-758F-4D1C-9EC8-818FBF9C1E03Q55284672-A53F3537-86E1-4B65-922A-233B3C681758Q58738114-09C31B11-F565-4B94-AC0E-D75036F0F799
P2860
Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@en
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@nl
type
label
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@en
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@nl
prefLabel
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@en
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@nl
P2093
P1433
P1476
Coexpression of the c-met prot ...... or in human pancreatic cancer.
@en
P2093
P304
P407
P577
1994-11-01T00:00:00Z